Clinical Trial Detail
| NCT ID | NCT02864251 |
| Title | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Bristol-Myers Squibb |
| Indications | |
| Therapies |
Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium |
| Age Groups: | senior adult |
CKB BOOST